ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
27 hedge funds and large institutions have $11.3M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
167% more call options, than puts
Call options by funds: $8K | Put options by funds: $3K
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
13% less funds holding
Funds holding: 31 → 27 (-4)
48% less capital invested
Capital invested by funds: $21.7M → $11.3M (-$10.4M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.26M |
| 2 |
Renaissance Technologies
New York
|
+$225K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$55.5K |
| 4 |
Millennium Management
New York
|
+$24.4K |
| 5 |
WW
Waterfront Wealth
Overland Park,
Kansas
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.75M |
| 2 |
O
OrbiMed
New York
|
-$1.75M |
| 3 |
Morgan Stanley
New York
|
-$134K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$95.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$19.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MP
26
Mangrove Partners
Greenwich,
Connecticut
| – | -$1.75M | -48,562 | Closed |
|
|
O
27
OrbiMed
New York
| – | -$1.75M | -48,530 | Closed |
|
|
SCM
28
Silverarc Capital Management
Boston,
Massachusetts
| – | -$1.59K | -12,500 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$6K | -159 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | +$200 | +9 | New |
|
ASLN Hedge Fund Activity: Q2 2022 in Review
27 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q2 2022, worth a combined $11.3M — down 48% from $21.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ASLN and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Tang Capital Management, adding an estimated $1.26M. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.75M sold.
- 27 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q2 2022, down from 31 in Q1 2022.
- Funds reported $11.3M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q2 2022, down 48% quarter-over-quarter.
- 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q2 2022 and 5 closed out, a net change of -4 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q2 2022 was Tang Capital Management, an estimated $1.26M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q2 2022 was Mangrove Partners, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2022.